John DiPersio is currently Professor of Medicine and Chief of the Division of Oncology at the Washington University School of Medicine (WUSM), St. Louis, MO, as well as being the Deputy Director at the Siteman Cancer Center and the Director of the Center for Gene and Cellular Immunotherapy, WUSM.
Prof. DiPersio completed his BA in biology at Williams College, Williamstown, MA, and his medical degree and PhD in microbiology at the University of Rochester, NY. He then completed his residency at Parkland Memorial Hospital, Dallas, TX, and a fellowship in hematology-oncology at the UCLA School of Medicine, Los Angeles, CA.
Additionally, Prof. DiPersio is an ethics advisory board member of various institutions, including the University of Chicago, the Sylvester Comprehensive Cancer Center, the University of Rochester, Weill Cornell Medicine, and Mt Sinai.
Speaking on hematopoietic growth factor receptors, murine models of GvHD, and leukemia genomics
Prof. DiPersio’s current research includes studies on identifying genetic abnormalities in human leukemias, understanding processes involving stem cell and leukemia cell trafficking, and clinical and translational programs in both leukemia and stem cell transplantation. His research utilizes unique mouse models of allogeneic stem cell transplantation to explore novel genetic and epigenetic interventions.
Prof. DiPersio is also involved in multiple clinical trials focused on the diagnosis and treatment of patients with hematologic malignancies or those undergoing allogeneic stem cell transplantation. Two such recent trials evaluate the effects of plerixafor, G-CSF, and azacitidine for the treatment of myelodysplastic syndromes and itacitinib in patients with acute graft-versus-host disease (GvHD).